Prolonged SARS-CoV-2 replication in an immunocompromised patient

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by a COVID-19 Response Innovation Grant from the University of Michigan. Additional support for the enrollment of hospitalized patients with COVID-19 was provided by the CDC (U01 IP000974).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Determined exempt by University of Michigan IRB. Residual clinical specimens were obtained under a protocol approved by the University of Michigan IRB.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes